Alnylam (ALNY) Q2 2026 Earnings Call Transcript
Alnylam (ALNY) reported Q2 2026 net product revenues of $1.2B, up 74%, driven by AMVUTTRA uptake in ATTR cardiomyopathy. TTR net product revenues were $1.03B, up 89%, and the company raised AMVUTTRA run rate to over $4B annually. It lowered 2026 product guidance to $4.7B-$5.1B and revised collaboration/royalty guidance to $575M-$625M.
How this was made
The 30-second read
Why it matters
The key tradable items are the quantified Q2 revenue metrics and the revised 2026 guidance ranges, especially the midpoint reduction tied to normalized second-line demand. Management also provided competitive and clinical framing (tafamidis generic delay, TRITON-CM outcomes, and comparative knockdown modeling).
Market read
Traders get a direct 2026 revenue guidance reset plus supporting datapoints on AMVUTTRA adoption and TRITON-CM conviction, which should drive expectation-setting for the next several quarters.
What to watch
Inventory dynamics and second-line demand normalization are cited as drivers; traders may also want to monitor how quickly first-line starts convert into durable revenue beyond the stated AMVUTTRA run-rate.
Background
This is a transcript-style earnings call covering Q2 2026 performance in Alnylam’s TTR franchise, including AMVUTTRA (ATTR cardiomyopathy) and nucresiran (TRITON-CM).
Ticker impact
Alnylam reported Q2 2026 results and revised full-year product revenue guidance, citing normalized second-line demand for TTR and AMVUTTRA uptake.
Likely choppy trading: initial relief from TTR franchise exceeding $1B in Q2, offset by the $200M midpoint product guidance reduction.
The article contains multiple quantified disclosures (Q2 revenues, run-rate, and revised guidance ranges) plus management’s explicit explanation for the downgrade, which should drive re-pricing around expectations for 2026 volumes and mix.
Market effects
Reinforces RNAi competitive positioning in ATTR cardiomyopathy versus ASO therapies, potentially affecting sentiment toward RNAi peers and ATTR franchise expectations.
Highlights international TTR revenue growth despite pricing headwinds, which may influence regional demand assumptions for ATTR therapies.
Guidance revision and competitive timeline (tafamidis generic delay) can affect broader amyloidosis treatment market pricing and adoption expectations.
Counterpoint
The guidance reduction suggests demand normalization is more persistent than management implies, and modeled nucresiran efficacy may not translate into realized outcomes or payer behavior.
Key entities
- companyAlnylam Pharmaceuticals
Subject of the earnings call transcript, reporting Q2 2026 results and revising full-year guidance for its TTR franchise.
- productAMVUTTRA
ATTR cardiomyopathy therapy whose uptake is cited as driving Q2 growth and a >$4B annual run-rate.
- productnucresiran
RNAi therapy in TRITON-CM, with management citing modeled TTR knockdown and clinical outcome updates.
- competitortafamidis
Stabilizer class whose U.S. generic entry is delayed until mid-2031, extending competitive window for AMVUTTRA.
